The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors
- 1 September 2017
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (18) , 4500-4505
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJournal of Medicinal Chemistry, 2017
- Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease2017
- LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?Current Neuropharmacology, 2016
- Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) InhibitorsJournal of Medicinal Chemistry, 2015
- Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase InhibitorJournal of Medicinal Chemistry, 2014
- Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Expert Opinion on Therapeutic Patents, 2014
- From Human Genetics to Drug Candidates: An Industrial Perspective on LRRK2 Inhibition as a Treatment for Parkinson's Disease2013
- Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule InhibitorsJournal of Medicinal Chemistry, 2012
- Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyondDrug Design, Development and Therapy, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011